Business
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Media ReleaseCOPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC’s website, www.sec.gov and Genmab’s website, www.genmab.com. About Genmab Genmab is an interna
About this update from Genmab A/s
[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Media ReleaseCOPENHAGEN, Denmark; February 17, 2026","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":68,"olType":false},{"type":"text","content":"Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC’s website, www.sec.gov and Genmab’s website, www.genmab.com.","length":345,"tagName":"p"},{"type":"text","content":"About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.","length":682,"tagName":"p"},{"type":"text","content":"Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.","length":222,"tagName":"p"},{"type":"text","content":"Contact: Marisol Peron, Senior Vice President, Global Communications &...